Typhoid conjugate vaccine proves its worth in the field
A new typhoid conjugate vaccine (TCV) that has been approved by the World Health Organization (WHO) Global Advisory Committee on Vaccine Safety has proved extremely effective in both young children and adults in a high-endemicity area for the first time. With almost 82% of recipients showing protection against typhoid, the vaccine promises to help control this deadly disease that claims up to 160,000 of its 11 million victims each year.
The TCV was carried out in Nepal, using a vaccine produced by Bharat Biotech, Hyderabad, India. By proving its efficacy, the test “provides the first evidence of the level of impact and the potential for improving the health of children in some of these very vulnerable populations around the world.” The research, titled 'Phase 3 Efficacy Analysis of a Typhoid Conjugate Vaccine Trial in Nepal', is published in the New England Journal of Medicine.
No hay comentarios:
Publicar un comentario